NCT05498545View on ClinicalTrials.gov

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2027

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
BIOLOGICAL

LUCAR-B68 cells product

Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen

Trial Locations (1)

710000

Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

Second Affiliated Hospital of Xi'an Jiaotong University

OTHER